GW Pharmaceuticals
Cannabinoid prescription medicines developer.
Launch date
Employees
Market cap
-
Enterprise valuation
$7.2b (Public information from Feb 2021)
Share price
$218.96 GWPH
Company register number 03704998
Histon England (HQ)
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 10.6m | 19.8m | 411m | 696m | 711m | 939m |
| % growth | - | - | 88 % | 1973 % | 69 % | 2 % | 32 % |
| EBITDA | (110m) | (210m) | (388m) | (144m) | (51.5m) | 86.0m | 197m |
| % EBITDA margin | - | (1988 %) | (1960 %) | (35 %) | (7 %) | 12 % | 21 % |
| Profit | 110m | (224m) | (403m) | (11.9m) | (76.6m) | 19.0m | 160m |
| % profit margin | - | (2125 %) | (2033 %) | (3 %) | (11 %) | 3 % | 17 % |
| EV / revenue | - | 418.4x | 158.9x | 8.7x | 5.9x | 11.9x | - |
| EV / EBITDA | - | -21.1x | -8.1x | -24.8x | -79.8x | 98.3x | - |
| R&D budget | 123m | 138m | 147m | 140m | - | - | - |
| R&D % of revenue | - | 1302 % | 744 % | 34 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $31.0m Valuation: $120m 5.0x EV/LTM EBITDA | IPO | |
| N/A | $87.9m | Post IPO Equity | |
| N/A | $179m | Post IPO Equity | |
* | N/A | $290m | Post IPO Equity |
* | N/A | $317m | Post IPO Equity |
* | N/A | €300m | Post IPO Equity |
$7.2b Valuation: $7.2b 10.3x EV/LTM Revenues -139.9x EV/LTM EBITDA | Acquisition | ||
| Total Funding | - | ||
Related Content
Recent News about GW Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.